A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.
Also called NCT02976467
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 107 participants
- Sponsor
- Registry
-
NCT02976467 -
2016-002167-33
-
- Other papers using this trial's data
- Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Czechia, Germany, Israel, Italy, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02976467. Randomized; quadruple masking; primary purpose treatment. Start 2016-12-30 (actual); primary completion 2018-07-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction
- Acronym
- CHIARA MIA 2
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Fulacimstat (BAY1142524)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct02976467- Content hash
747825323ac6d6c474e8c313131bd19676bc28e3278a0aaa848fb857510a508f